Analyst Presentation and fact sheet - financial results for the quarter ended June 30, 2026

INDGN/SE/2026-27/38 30 July 2026 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam, Subject: Analyst presentation and fact sheet - financial results for the quarter ended June 30, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), the Analyst presentation and fact sheet with respect to financial results for the quarter ended June 30, 2026, are hereby enclosed. The above information will be made available on the website of the Company: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 Investor Presentation Q1’FY27 Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the statements themselves. Such statements comprise the company’s current visibility on market movements, client discussions, and related factors. Indegene Limited does not assume an obligation to update or revise any forward-looking statements. © 2026 Indegene. All rights reserved. 2 Quarterly Performance Q 1’FY27 A Quarter of significant growth at scale RE VE N U E FROM OPE RAT ION S INR 10,631 M USD 112.5 M ▲ 39.7% ▲ 6.0% ▲ 26.5% ▲ 2.5% YoY in INR QoQ in INR YoY in USD QoQ in USD E B I T D A P A T D S O R P E ₹ 1,795 M ₹ 1,162 M 67 Days $ 77.1 K 16.9% of Revenue 10.9% of Revenue ▲ 16.9% YoY ▲ 8.9% QoQ  0.2% YoY ▲ 45.9% QoQ  4 days YoY ▲ 4 days QoQ ▲ 14.2% YoY ▲ 3.2% QoQ © 2026 Indegene. All rights reserved. 3 Revenue Re-Acceleration with Resilient Margins +39.7% 16.9% 10.9% Q1’FY27Revenue Growth YoY Q1’FY27EBITDA Margin Q1’FY27 PAT Margin REVENUE (₹ M) EBITDA & PAT MARGIN (%) 10,631 10,034 9,421 8,042 20.2% 7,608 17.6% 17.5% 16.9% 16.4% 15.3% 12.7% 10.9% 10.9% 7.9% Q1'FY26 Q2'FY26 Q3'FY26 Q4'FY26 Q1'FY27 Q1'FY26 Q2'FY26 Q3'FY26 Q4'FY26 Q1'FY27 EBITDA Margin PAT Margin © 2026 Indegene. All rights reserved. 4 Two Growth Engines Driving Revenue Expansion Deeper penetration of top accounts and a wider, taller client pyramid are compounding revenue growth G R O W T H A P P R O A C H 1 G R O W T H A P P R O A C H 2 Deeper Engagement with Large Pharma Broader Targeting — Wider, Taller Pyramid ₹7,080M ₹3,231M 3 of 5 105 54 +59 Top-20 revenue in Q1’27 Top-5 revenue in Q1’27 Top-5 customers Active clients⁽¹⁾ $1M+ clients Active clients added Q1’FY27 TTM, +9.5% QoQ Q1’FY27 TTM, +3.4% QoQ now at $25 M+ Q1’FY26: 70 – 35 new additions Q1’FY26: 40 – 14 new additions since FY22 Revenue from Top-5 & Top-20 customers (₹ M) Growing accounts by revenue tier (count of clients) $1M–$10M $10M–$25M $25M+ Top 20 Top 5 3 3 26,480 24,190 21,657 22,082 2 19,321 14,320 4 6 11,345 11,984 11,347 12,078 12,491 2 43 42 9,176 26 26 FY22 FY23 FY24 FY25 FY26 Q1'FY27 TTM FY22 FY23 FY24 FY25 FY26 Q1'FY27 Strong growth trajectory across our top 20 accounts over the years underscores $1M+ clients nearly doubled from 28 in FY22 to 54 in Q1’FY27. deepening client relationships, sustained demand and healthy NRR. 1.Active clients with revenue of $0.25 M or more over the trailing twelve months rounded off to nearest thousands. © 2026 Indegene. All rights reserved. 5 Q1’FY27 Business Highlights Expanding customer base | Improving revenue productivity | Strengthening global delivery Customer Growth & Productivity Global Delivery Excellence ACTIVE CLIENT RELATIONSHIPS⁽¹⁾ 105 HEALTHCARE DELIVERY EXPERTISE 29.0% Clients served Share of delivery team with domain skills Q1’FY26 : 70 ▲ 35 new clients | 50.0% Q1’FY26 : 24.8% ▲ 420 bps YoY CLIENTS WITH $1M+ REVENUE 54 VOLUNTARY ATTRITION (TTM) 15.7% Deepening wallet share Improving retention signals Q1’FY26 : 40 ▲ 14 new addition | 35% Q1’FY26 : 16.8% ▼ 110 bps improvement REVENUE PER EMPLOYEE $77.1K TOTAL / DELIVERY EMPLOYEES(2) 5,826 / 4,983 Operating leverage driver Scaling global delivery capacity Q1’FY26 : $67.5K ▲ 14.2% YoY Q1’FY26 : 5,087 / 4,394 ▲ 14.5% / 13.4% YoY 1.Active clients with revenue of $0.25 M or more over the trailing twelve months rounded off to nearest thousands. 2. Includes overseas contract resources on third-party payrolls currently being transitioned to direct employment. © 2026 Indegene. All rights reserved. 6 Management Commentary on Q1 FY’27 results We started FY27 strongly, delivering sequential USD revenue In Q1FY27, we delivered 39.7% YoY revenue growth in INR terms and growth of 2.5% - our strongest sequential growth in a first 26.5% in USD. We expanded our active client base by 14 sequentially quarter in four years - and expanding our active client base to to 105. The increase in active clients reflects our investments in more than 100. We improved productivity, with revenue per strengthening our sales and go-to-market teams last year. Profitability employee rising to $77K - the highest in our peer group. We improved in step with growth, with both EBITDA and PAT margins also deepened our client relationships, with 12 customers now expanding sequentially. As these investments mature and ongoing generating more than $10 million in annual revenue each. We engagements scale, we expect operating leverage to improve further are focused on developing and scaling differentiated products, and profitability to strengthen in the second half of the year. solutions and GenAI-powered technologies to advance AI- driven life sciences commercialization and drive the next phase of our growth. Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer © 2026 Indegene. All rights reserved. 7 Indegene is a new category – not a better version of an old one Embedded Revenue Partner $77.1K • Operate in clients' revenue-generating engine: Commercial & Med teams behind launches, brands & growth REVENUE / EMPLOYEE • Sit on growth-side budgets, not IT cost budgets; less exposed to cost-cutting cycles — HIGHEST IN • Productivity-benefit gets redeployed as increased volume: personalized content and more channels INDUSTRY Deep Domain Expertise D 29%+ • With over 27 years of experience in life sciences, we are deeply integrated in client workflows; • Manage critical workflows requiring high degree of domain expertise and regulatory compliance EMPLOYEES FROM • Judgment-intensive work where GenAI compounds domain knowledge rather than replacing it HEALTHCARE GenAI Disruptor • Pharma companies face complexity explosion (content volume & regulatory compliance) & fragmented non-standardized G models resulting in efforts to centralize operations • Our AI-enabled solutions engage at enterprise level (not brand-by-brand) to re-engineer & re-imagine end-to-end YEARS OF DELIVERING processes, thus accelerating this transformation & taking wallet share from incumbents AI • GenAI price deflation pressures large incumbents but provides growth headroom for us at our current scale Engagement Model E ~60% • Global delivery model with multi-geography governance & standardization generating productivity at scale • Majority revenue is outcome-aligned — paid for work delivered and value created REVENUE OUTCOME-ALIGNED We don't fit the IT-services, • Efficiency gains flow to the bottom line, creating incentive to adopt and scale newer technologies faster Agency or CRO box. © 2026 Indegene. All rights reserved. 8 Strategic P [Showing first 8,000 characters — download PDF for full document]